Who are Global Blood Therapeutics's investors?

Global Blood Therapeutics's investors include Aisling Capital, Avoro Capital Advisors, RA Capital, Ridgeback Capital, Third Rock Ventures, Wellington Management.

How much funding has Global Blood Therapeutics raised?

Global Blood Therapeutics has disclosed $48M raised across 1 round.

Who acquired Global Blood Therapeutics?

Global Blood Therapeutics was acquired by Pfizer.

Where is Global Blood Therapeutics headquartered?

Global Blood Therapeutics is headquartered in South San Francisco, US.

Global Blood Therapeutics

Unicorn exit · $5.4Bacquired by Pfizer

South San Francisco, US · Founded 2011 · Delaware corporation · 72 employees on LinkedIn · 6 known investors

Find your way into Global Blood Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Global Blood Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Acquired by Pfizer August 2022 · $5.4B ($68.50 per share cash, ~$5.4 billion total enterprise value) · source ↗

Global Blood Therapeutics was a South San Francisco biopharmaceutical company founded in 2011 focused on treatments for sickle cell disease. It developed Oxbryta (voxelotor), the first FDA-approved drug directly inhibiting sickle hemoglobin polymerization.

Founders & leadership

John Schembri Vice President Finance and Controller2014–2016John Schembri is an Executive Officer at Global Blood Therapeutics, a biopharmaceutical company focused on sickle cell disease treatments. He brings finance and accounting expertise, with a background in public and private equity fundraising and leading multiple biotechnology company acquisitions totaling over $3.6 billion.

Ted W. Love President & CEO2014–2022Ted W. Love earned his medical degree from Yale School of Medicine and spent approximately a decade in clinical practice before moving into biopharmaceutical leadership, serving as President and CEO of Global Blood Therapeutics where he oversaw development of therapies for sickle cell disease.

Board

Kevin Starr Board Member2012–2016Investor at Third Rock Ventures

Charles Homcy, M.D.Board director

Investors · 6

Aisling Capitallisted by Aisling CapitalNew York

How we know: Aisling Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Avoro Capital Advisorslisted by Avoro Capital AdvisorsNew York

RA Capitallisted by RA CapitalBoston

How we know: RA Capital's portfolio page · Not right? Tell us

Ridgeback Capitallisted by Ridgeback CapitalNew York

How we know: Ridgeback Capital's portfolio page · Not right? Tell us

Third Rock VenturesreportedBoston · $100K – $5Mvia Kevin Starr · board

How we know: board seat on SEC Form D · funding news · Not right? Tell us

Wellington ManagementreportedBoston · $5M – $50M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$48M disclosed across 1 round · 2014

▶$48MraisedJan 2015 · 13 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Kevin StarrDirector
John SchembriExecutive Officer
Charles Homcy, M.D.Director
Ted W. LoveExecutive Officer, Director

Offering amount: $48M
Amount sold: $48M
First sale: Dec 2014
Incorporated: Corporation, Delaware, 2011
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Global Blood Therapeutics do?: Global Blood Therapeutics was a South San Francisco biopharmaceutical company founded in 2011 focused on treatments for sickle cell disease. It developed Oxbryta (voxelotor), the first FDA-approved drug directly inhibiting sickle hemoglobin polymerization.
Who are Global Blood Therapeutics's investors?: Global Blood Therapeutics's investors include Aisling Capital, Avoro Capital Advisors, RA Capital, Ridgeback Capital, Third Rock Ventures, Wellington Management.
How much funding has Global Blood Therapeutics raised?: Global Blood Therapeutics has disclosed $48M raised across 1 round.
Who acquired Global Blood Therapeutics?: Global Blood Therapeutics was acquired by Pfizer.
Where is Global Blood Therapeutics headquartered?: Global Blood Therapeutics is headquartered in South San Francisco, US.